Background: Although anti-tumour necrosis factor agents (anti-TNFs) are very effective in most patients with ankylosing spondylitis (AS) significant proportion of patients quit the treatment due to non-response or adverse events. The development of anti-drug antibodies (ADAs) and low serum drug levels might have a mechanistic role in loss of efficacy of or the development of adverse events in patients treated with anti-TNFs. There is limited data regarding the immunogenicity of anti-TNFs in patients with AS. Objectives: Therefore the aim of this study was to evaluatethe relationship between the formation of ADAs, serum through drug levels and clinical response to anti-TNFs in patients with AS. Methods: In total 350 AS patients with a new anti-TNF agent prescription in the last two weeks period were planned to include this multi-center prospective observational cohort study. Herein we are presenting the data of first 102 patients who had >3months follow-up. Clinical data and serum samples were collected at baseline and at every three months of treatment. Serum drug levels and ADAs were measured by ELISA in one center to avoid inter-assay variability. 
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Results

Conclusions:
The physical therapy and rehabilitation has led to the improvement the respiratory index in patients with AS, which confirms its effectiveness. The value of respiratory index at beginning rehabilitation is associated with duration of the rehabilitation. Significant limitation in respiratory index indicates longer hospital stay. These results could be having importance in planning of rehabilitation of patients with AS. Background: Limited data are available on the influence of gender and lifestyle factors, such as smoking, alcohol consumption and Body Mass Index (BMI) on disease activity and response to TNF inhibitors (TNFi) in ankylosing spondylitis (AS). Objectives: This study aimed to determine whether these factors influence age at diagnosis, disease activity and response to TNFi. Methods: In a prospective study, clinical data (age, gender, C-reactive protein, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI), smoking, alcohol consumption and BMI) were collected in AS patients from a observational cohort, who started or switched treatment with TNFi. Data were collected at baseline and after 6, 12 and 24 months. Independent T-tests and linear regression analyses were performed to assess the influence of gender and lifestyle factors on age at diagnosis and disease activity.
